 SAI | SAIC, Inc. announced that John P. Jumper will succeed Walter P. Havenstein as CEO on Mar 1, 2012. Jumper joined SAIC's board as Director in June, 2007. From Sep 2001 to Novr 2005, Jumper was the Chief of Staff of the United States Air Force. Havenstein, who has led the company since September of 2009, announced his retirement in October, 2011. Jumper, who will remain a member of SAIC's Board of Directors, retired from the United States Air Force in 2005 after nearly 40 years of service. He has also served at the Pentagon as Deputy Chief of Staff for Air and Space Operations. |
SAIC Appoints Board Member John P. Jumper as CEO
February 21, 2012
Medtronic Get FDA Approval for Resolute Integrity Drug-Eluting Stent
February 17, 2012
 MDT | Medtronic Inc. announced U.S. FDA approval of the Resolute Integrity Drug-Eluting Stent (DES) for the treatment of coronary artery disease (CAD). The new heart device’s FDA approval stems from the results of a global series of studies involving the Resolute DES, which showed consistently powerful clinical performance across a broad spectrum of patients. |
Rovi Corporation Lowers FY 12 Guidance
February 16, 2012
 ROVI | Rovi Corporation expects FY 12 pro forma adjusted revenues to range between $755 million and $785 million, down from previous guidance of $810 to $840 million; and adjusted pro forma EPS to range between $2.35 and $2.65, down from previous guidance of $2.50 to $2.80. The guidance was issued in 4Q and FY 11 earnings release. |
 BCRX | BioCryst Pharmaceuticals Inc. announced favorable preclinical results for BCX5191, a novel adenine nucleoside analog targeting viral RNA polymerase for the potential treatment of hepatitis C. BioCryst successfully completed in vitro and in vivo studies in which BCX5191 exhibited potent and selective pan-genotypic antiviral activity against the hepatitis C polymerase enzyme. BCX5191 showed no inhibition of human RNA polymerase and no evidence of toxicity from standard in vitro screens. |
Watson Pharma Raises FY 12 Earnings Guidance
February 14, 2012
 WPI | Watson Pharmaceuticals, Inc. now expects FY 12 net revenue of $5.4 billion, compared to prior guidance of $5.3 billion; GAAP net income of $340 to $380 million or $2.64 to $2.95 per share, compared to prior guidance of $315 to $354 million or $2.44 to $2.75 per share; non GAAP net income of $709 to $747 million or $5.50 to $5.80 per share, compared to prior guidance of $677 to $716 million, or $5.25 to $5.55 per share; and adjusted EBITDA of $1.300 to $1.375 billion, compared to prior guidance of $1.28 to $1.35 billion. The company expects FY 12 EBITDA of $1.239 to $1.314 billion. The guidance was provided along with its 4Q 11 earning results. |
Timken Hikes Quarterly Dividend 15%
February 13, 2012
 TKR | Timken Company declared a quarterly cash dividend of $0.23 per share, an increase of 15% over the previous quarterly amount. This dividend on the common stock of the company payable on Mar 2, 2012, to shareholders of record as of Feb 21, 2012. |
Kimco Realty Raises FY 12 EPS Guidance
February 8, 2012
 KIM | Kimco Realty Corporation reported results for 4Q 11 and raised FY 12 outlook. The Company now expects FY 12 EPS of $0.32 to $0.35, compared to prior guidance of $0.31 to $0.34. The company continues to expect FY 12 recurring FFO of $1.22 to $1.26 per share. |
CNA Financial Hikes Quarterly Dividend 50%
February 6, 2012
 CNA | CNA Financial Corporation declared of a quarterly dividend of $0.15 per share, an increase of 50% from last quarter dividend of $0.10 per share, payable Mar 1, 2012 to stockholders of record on Feb 16, 2012. |
Hasbro Hikes Quarterly Dividend 20%
February 2, 2012
 HAS | Hasbro, Inc. declared a quarterly cash dividend of $0.36 per share, an increase of $0.06 per share, or 20%, from the previous quarterly dividend of $0.30 per common share. The dividend will be payable on May 15, 2012 to shareholders of record on May 1, 2012. |
BMC Software Raises FY 12 EPS Guidance
February 1, 2012
 BMC | BMC Software Inc. now expects FY 12 non-GAAP EPS to be in the range of $3.26 to $3.34, up from prior forecast of $3.21 to $3.31 and cash flow from operations to be between $775 million and $825 million, revised from prior forecast of between $800 million and $850 million and operating margin to be slightly up from the prior year. The company continues to expect revenue growth in the mid-single digits. The guidance was provided in 3Q 12 earnings release. |
